智通财经APP获悉,3月27日,中国国家药监局药品审评中心(CDE)官网最新公示,礼来(LLY.US)申报的1类新药注射用LY4052031获批临床,拟单药用于治疗晚期或转移性尿路上皮癌或其他实体瘤。公开资料显示,这是一款在研的抗Nectin-4抗体偶联药物(ADC),正在国际范围内开展1期临床研究。本次是该产品首次在中国获批IND。Nectin-4是一种免疫球蛋白样抗原,在多种癌症中过表达,包括...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.